2026国谈第五日:商保创新药目录价格协商开始 多家药企携核药、CAR-T新药等重磅药物进场

格隆汇
Sep 09
今日八时许,2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商第五日正式开启,今日是今年国谈的最后一日,将密集进行商保创新药目录价格协商,基本医保目录谈判竞价已于昨日上午完成。阿斯利康、赛诺菲、科济药业子公司恺兴生命、远大、恒润达生、精准生物等企业代表陆续进入谈判会场。今年商保创新药目录价格协商共有62个药品通用名申报,58个通过形式审查,其中目录外57个、目录内1个,罕见病、肿瘤、神经系统疾病仍是申报主力,合计占比约七成,恒润达生的雷尼基奥仑赛注射液、精准生物的普基奥仑赛注射液两款CAR-T新药首次尝试“闯关”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10